Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.

Wade DT, Robson P, House H, Makela P, Aram J.

Clin Rehabil. 2003 Feb;17(1):21-9.

PMID:
12617376
2.
4.
5.

Sativex for the management of multiple sclerosis symptoms.

Perras C.

Issues Emerg Health Technol. 2005 Sep;(72):1-4.

PMID:
16317825
6.

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.

Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group.

Eur J Neurol. 2007 Mar;14(3):290-6.

PMID:
17355549
7.

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.

Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ.

Mult Scler. 2004 Aug;10(4):425-33.

PMID:
15327041
10.

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.

Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S.

J Neurol. 2013 Apr;260(4):984-97. doi: 10.1007/s00415-012-6739-4. Epub 2012 Nov 21.

PMID:
23180178
11.
12.

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

Rog DJ, Nurmikko TJ, Friede T, Young CA.

Neurology. 2005 Sep 27;65(6):812-9.

PMID:
16186518
13.

Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.

Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK.

Curr Pharm Des. 2012;18(32):4966-79. Review.

PMID:
22716148
14.

Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.

Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, Curran HV.

Eur Neuropsychopharmacol. 2015 Mar;25(3):325-34. doi: 10.1016/j.euroneuro.2014.11.014. Epub 2014 Dec 5.

15.

An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.

Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT.

J Pain Symptom Manage. 2013 Aug;46(2):207-18. doi: 10.1016/j.jpainsymman.2012.07.014. Epub 2012 Nov 8.

PMID:
23141881
16.

Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.

Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, Rivas GR, Holland RM, Muhleisen P, Norberg MM, Booth J, McGregor IS.

JAMA Psychiatry. 2014 Mar;71(3):281-91. doi: 10.1001/jamapsychiatry.2013.3947.

PMID:
24430917
17.

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.

Lakhan SE, Rowland M.

BMC Neurol. 2009 Dec 4;9:59. doi: 10.1186/1471-2377-9-59. Review.

18.

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.

Syed YY, McKeage K, Scott LJ.

Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Review.

PMID:
24671907
19.

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Gras A, Broughton J.

Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):771-779. Epub 2016 Feb 26.

PMID:
26750641
20.

Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.

Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C.

Anaesthesia. 2004 May;59(5):440-52.

Supplemental Content

Support Center